The board of directors of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced that Mixed Protamine Human Insulin Injection (30R) (the ``Product''), independently researched and developed by the Company, has undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration. Name of the drug (English) Mixed Protamine Human Insulin Injection (30R): Form: Injection. Specification: 3ml: 300 units (prefilled pen-type).

Registration category: Biological products for treatment. Handling number: CXSS2200010Guo. Drug approval number: Guoyaozhunzi S20230051.

Certificate number: 2023S01450. The Product is a premixed insulin product for treatment of diabetes. It consists of 30% soluble human insulin and 70% protamine human insulin.

The Product is suitable for the treatment of diabetes through subcutaneous injection, characterised by its low incidence of hypoglycemia and being safe for use, can effectively control postprandial blood glucose, fasting blood glucose and glycosylated hemoglobin (HbA1c) levels. According to the market data from IMS China, the sales volume of diabetes drugs in China in 2022 reached approximately USD 4.84 billion, amongst which approximately 39.5% of the total sales of diabetes drugs in the market was attributable to the sales of domestic human insulin and its analogue drugs for 2022, indicating a considerable market potential. The Product is a biological drug of the Group approved for launch.

The cumulative research and development expense we invested in it was approximately RMB130.1 million. Moreover, the Group has long been involved in the treatment of diabetes with a comprehensive product plan and a complete product line in place. The Product being successfully approved for launch will be beneficial for the expansion of the Group's business of treating endocrine and metabolic diseases and further enrich the Group's product portfolio.